You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis

    SBC: GLYCOMIRA, LLC            Topic: NIAID

    PROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: NIEHS

    Summary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Large Pore SPP Particles for Protein Separations

    SBC: ADVANCED MATERIALS TECHNOLOGY, INC.            Topic: 400

    AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: NCI

    ABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Wafer-Level Electronic-Photonic Co-Packaging

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: AF16AT01

    In phase II work, we will collaborate with Prof. Stefan Preble in RIT and continue to develop large scale hybrid integration and packaging techniques for key active photonic components such as lithium niobate on insulator (LNOI) modulators and modified uni-traveling (MUTC) photodiodes. We will demonstrate a low V, broadband, small footprint LNOI modulator with hybrid Si/LN or SiN/LN waveguide usin ...

    STTR Phase II 2018 Department of DefenseAir Force
  7. Instant k-Space Tomography for Spatial-Spectral Monitoring

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: AF17AT013

    The Army is frequently forced to operate in hostile climates. Heavy fog, rain, snow, and dust storms can inhibit the performance of tracking technologies such as mid-wave infrared cameras. In such conditions, Army early warning systems are blinded and put personnel and assets at risk.There is a specific need for a degraded visual environment (DVE) penetrative target tracking solution.Radio frequen ...

    STTR Phase II 2018 Department of DefenseAir Force
  8. Develop integrated analog photonic modulator components compatible with photonic foundry production

    SBC: PHASE SENSITIVE INNOVATIONS INC            Topic: AF171126

    In phase II work, we will collaborate with Prof. Dennis W. Prather in UD and continue to develop broadband, low VÏ€, high linearity, thin-film lithium niobate on insulator (LNOI) modulators that are fully compatible with silicon photonic integrated circuits (PIC) foundry processes. We will demonstrate a low VÏ€, broadband, small footprint LNOI modulator with hybrid Si/LN or SiN/LN waveguide ...

    SBIR Phase II 2018 Department of DefenseAir Force
  9. Precision quality check of immunotherapeutics via single-cell cytokine mapping

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Adoptive transfer of autologous T cells engineered to express chimeric antigen receptorsCARshas emerged as a promising immunotherapy for patients with hematologic malignanciessuch as CDCARs in leukemias and lymphomasHoweverchallenges remain in terms of manufacturing consistency and the functional profile of the CAR T cell productsince infused cellsasliving drugscan be activated and release a varie ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. A single-cell device to capture and analyze rare T-cells from solid tumors.

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Checkpoint inhibitors towards targets such as PDand PD Lare being developed to activate quiescent T cells embedded in tumors and enable them to recruit the rest of the immune system to fight a cancer massHow these new cures reactivate the relatively few Tumor Infiltrating LymphocytesTILsenabling the release of a complex message of cytokines to recruit the immune systemthus impacting treatment effi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government